The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Acute GVHD Treatment: Cyclosporine and Ruxolitinib for Steroid-Refractory Disease

Sequential immunosuppressive strategies for acute graft-versus-host disease management

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Hematoloji department. Book Appointment →

What is Acute GVHD Treatment: Cyclosporine and Ruxolitinib for Steroid-Refractory Disease?

Acute GVHD develops from donor T-cell recognition of recipient tissues as foreign producing inflammatory damage to skin, gastrointestinal tract and liver.

Grading system from I to IV based on organ involvement extent guides treatment intensity and prognosis.

Calcineurin inhibitor cyclosporine or tacrolimus combined with methotrexate or mycophenolate represents standard prophylaxis.

Posttransplant cyclophosphamide emerging as alternative prophylaxis particularly with haploidentical donors.

Steroid-refractory aGVHD historically had poor prognosis until ruxolitinib demonstrated superior outcomes.

Symptoms

Skin GVHD presents with maculopapular rash, erythroderma or bullous lesions affecting palms, soles and trunk.
Gastrointestinal GVHD includes diarrhea, abdominal pain, nausea, vomiting and gastrointestinal bleeding.
Hepatic GVHD presents with cholestatic liver injury and hyperbilirubinemia.
Severity grading considers extent of skin involvement, diarrhea volume and bilirubin elevation.
Differential diagnosis includes infection, drug toxicity and other transplant complications requiring biopsy when uncertain.

Risk Factors

HLA-mismatched donor including haploidentical transplantation increases aGVHD risk.
Donor-recipient sex mismatch (female donor to male recipient) increases risk.
Older recipient age and comorbidities affect aGVHD development and treatment tolerance.
Prior exposures including transfusions, pregnancy increase risk through alloimmunization.
Conditioning regimen intensity influences GVHD development and treatment response.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Post-transplant skin rash, diarrhea or liver function abnormalities require urgent evaluation for GVHD.
  • Inadequate response to corticosteroid therapy after several days warrants ruxolitinib consideration.
  • Severe gastrointestinal GVHD with massive diarrhea requires aggressive management and steroid-refractory therapy.
  • Infection complications during GVHD treatment require prompt antimicrobial therapy.
  • Long-term follow-up monitors chronic GVHD development, treatment-related complications and quality of life.

Treatment Methods

01
First-line prednisone 2 mg/kg/day or methylprednisolone equivalent for grade II-IV aGVHD.
02
Continued calcineurin inhibitor at therapeutic levels alongside corticosteroid treatment.
03
Ruxolitinib 10 mg twice daily for steroid-refractory aGVHD with documented superior efficacy versus best available therapy.
04
Supportive care including nutritional support, infection prophylaxis, transfusion support during cytopenia.
05
Comprehensive management including topical therapy for skin involvement, anti-diarrheal agents and parenteral nutrition for GI involvement, infection prevention with antifungal and antiviral prophylaxis, monitoring for chronic GVHD development with characteristic skin, mucous membrane and other organ involvement and gradual immunosuppression tapering after response with goal of immune reconstitution while preventing GVHD recurrence optimizes outcomes after this serious transplant complication.

Which Department to Visit?

You can visit our Hematoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Hematoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.